# South Korea Compounding Chemotherapy Market > South Korea Compounding Chemotherapy Market Research Report By Dose (Chemotherapeutic, Non-Chemotherapeutics), By Delivery Method (Gravimetric Automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-Sterile), and By Technology (With Robotic Arms, Without Robotic Arms) - Forecast to 203 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.01% - **2024:** $ 10.6 Million - **2025:** $ 11.24 Million - **2035:** $ 20.15 Million - **Key Players:** Fresenius Kabi (DE), Baxter International (US), Civica Rx (US), PharMEDium Services (US), Compounding Pharmacy of America (US), Avella Specialty Pharmacy (US), PillPack (US), Onco360 (US) **Report ID:** MRFR/Pharma/51473-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-compounding-chemotherapy-market-53234 --- ## Market Summary ## **South Korea Compounding Chemotherapy Market Overview** As per MRFR analysis, the South Korea Compounding Chemotherapy Market Size was estimated at 12.5 (USD Million) in 2023. The South Korea Compounding Chemotherapy Market Industry is expected to grow from 13.25(USD Million) in 2024 to 33.9 (USD Million) by 2035. The South Korea Compounding Chemotherapy Market CAGR (growth rate) is expected to be around 8.915% during the forecast period (2025 - 2035). **Key South Korea Compounding Chemotherapy Market Trends Highlighted** The South Korea Compounding Chemotherapy Market is witnessing significant trends driven by the increasing prevalence of cancer and a growing emphasis on personalized medicine. In recent years, the South Korean government has actively promoted initiatives aimed at improving cancer treatment outcomes, which has resulted in a heightened demand for customized chemotherapy solutions. This focus on precision cancer treatment aligns well with advancements in compounding technology, enabling healthcare providers to prepare tailored medications that meet individual patient needs more effectively.  Additionally, the implementation of stringent regulatory frameworks by the Ministry of Food and Drug Safety (MFDS) is shaping the market dynamics, as compliance with these regulations is essential for pharmaceutical companies involved in compounding chemotherapy.The new regulations are promoting innovation in the area while maintaining patient safety and product standards, which increases market growth opportunities.  There is also a growing partnership trend between pharmaceutical companies and compounding pharmacies to better develop the formulated compounds and new delivery methods for chemotherapy agents. This not only optimizes the treatment protocols but also makes it easier to manage the supply chain that is crucial for drug delivery. In addition, the more health-conscious consumers become aware of their treatment options, the more compounding pharmacies can educate the patients and doctors on the advantages of bespoke chemotherapy, which increases patient involvement and services offered. Overall, the South Korea Compounding Chemotherapy Market continues to evolve, influenced by regulatory support, technological advancements, and the increasing need for personalized treatment options, thereby positioning itself for sustained growth and innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **South Korea Compounding Chemotherapy Market Drivers** **Rising Incidence of Cancer in South Korea** The South Korea Compounding Chemotherapy Market Industry is witnessing significant growth due to the increasing incidence of cancer in the region. According to the Korea Central Cancer Registry, the number of cancer patients has risen drastically, reporting an increase from approximately 230,000 cases in 2010 to nearly 400,000 cases in 2020. This alarming rise of around 74% over the decade underscores the urgency for effective chemotherapy treatments. The Korean Ministry of Health and Welfare has also recognized the need for improved access to compounding chemotherapy options, further facilitating market growth. As the healthcare system enhances its focus on providing specialized cancer treatments, the demand for compounded chemotherapy drugs is expected to increase correspondingly. **Advancements in Pharmaceutical Technology** Innovations in pharmaceutical technology significantly impact the South Korea Compounding Chemotherapy Market Industry, driving the demand for sophisticated compounding services. The Korean Pharmaceutical Industry Association indicates that the local pharmaceutical sector has invested heavily in Research and Development (R&D), leading to the introduction of newer, more efficient drug formulations.  For instance, the advancement in automated compounding systems is enhancing drug precision and reducing human error, aligning with the stringent safety standards set by the Ministry of Food and Drug Safety.These technological advancements translate to better patient outcomes and increase trust in compounded chemotherapy solutions. **Supportive Government Policies** The South Korean government has introduced several initiatives aimed at improving cancer treatment accessibility, which is crucial for the South Korea Compounding Chemotherapy Market Industry. Policies promoting national health insurance coverage for cancer treatments were updated in recent years, allowing more patients to access necessary compounded chemotherapy drugs without a significant financial burden.  This has led to a more optimistic outlook on chemotherapy services in the country, with the National Health Insurance Service reporting an increase in approvals for cancer treatment costs by 30% year-on-year.Such policies not only help in patient retention but also stimulate market growth through increased demand for compounded formulary drugs. **Increasing Awareness and Education Campaigns** Public awareness campaigns focusing on cancer symptoms and treatment options significantly enhance the South Korea Compounding Chemotherapy Market Industry growth. Organizations such as the Korean Cancer Society are actively engaged in educating the public about the importance of early detection and prompt treatment.  Survey data from these campaigns indicate that around 65% of South Koreans are now better informed about chemotherapy options than five years ago.This growing awareness drives patient engagement in their treatment decisions, leading to increased consultations for compounded chemotherapy solutions. As more patients understand the benefits, the market is poised for continued growth. **South Korea Compounding Chemotherapy Market Segment Insights** **Compounding Chemotherapy Market Dose Insights** The South Korea Compounding Chemotherapy Market's Dose segment encompasses a broad range of applications essential for tailored cancer treatment, catering to the unique needs of patients across the nation. Within this segment, the importance of both Chemotherapeutics and Non-Chemotherapeutics cannot be understated, as they play distinct yet complementary roles in the therapeutic landscape.  Chemotherapeutics, designed to directly target and kill cancer cells, typically incorporate various agents and protocols that are critical for optimizing efficacy and minimizing side effects. This demand for precise dosing is driven by the increasing prevalence of cancer in South Korea, prompting healthcare professionals to focus on personalized treatment regimens that yield better outcomes for patients. On the other hand, Non-Chemotherapeutics are gaining traction as they offer alternative therapeutic avenues, including the use of biological agents and supportive treatments that enhance the overall efficacy of chemotherapy.  The integration of non-chemotherapeutic options is particularly important in managing the side effects associated with traditional chemotherapy, offering patients an opportunity for improved quality of life during treatment. The ongoing advancements in Research and Development are paving the way for novel formulations and complex combinations that strengthen the overall approach to cancer treatment in South Korea. Furthermore, regulatory frameworks in South Korea provide a conducive environment for the growth and innovation of the compounding chemotherapy market, ensuring that these specialized doses are safely and effectively administered.  The rising awareness among healthcare providers regarding the importance of customized chemotherapy protocols also drives the growth of the Dose segment. Patient-centric approaches, driven by collaboration among oncologists, pharmacists, and compounding specialists, underscore the potential of both Chemotherapeutics and Non-Chemotherapeutics in meeting the evolving demands of treatment paradigms.Challenges persist, however, as the market must navigate stringent regulations and the need for continuous education among healthcare providers about emerging therapies.  The SC (South Korea) healthcare system is characterized by a high level of sophistication, and there is significant pressure to ensure that all compounding practices align with the latest clinical guidelines and safety standards. As the landscape evolves, opportunities abound for stakeholders ready to invest in innovative solutions that offer reliable, effective dosing in chemotherapy. The sustained growth in the South Korea Compounding Chemotherapy Market is a direct reflection of the increasing commitment to enhance patient care through tailored therapy options, with the Dose segment standing as a critical pillar in this ongoing journey towards a more effective and compassionate approach to managing cancer. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **Compounding Chemotherapy Market Delivery Method Insights** The Delivery Method segment of the South Korea Compounding Chemotherapy Market is witnessing significant developments, with both Gravimetric Automated Compounding Devices and Volumetric Automated Compounding Devices playing crucial roles in shaping the industry landscape. Gravimetric Automated Compounding Devices are preferred for their precision in dosing, ensuring accurate drug preparation, which is essential in chemotherapy, where dosage impacts treatment efficacy and patient safety.  Meanwhile, Volumetric Automated Compounding Devices offer flexibility and efficiency in preparing complex medication mixtures, making them particularly beneficial in high-volume pharmacy settings.Both device types cater to the increasing demand for safety and efficiency in drug preparation within healthcare institutions, especially as South Korea's healthcare system continues to evolve with a focus on technology integration. The growing adoption of automated solutions in oncology settings in South Korea is driven by the need to reduce human errors and enhance workflow efficiency, thereby supporting better patient outcomes. As these delivery methods are integrated into standard practices, they reaffirm their importance in advancing the Compounding Chemotherapy Market in the region. **Compounding Chemotherapy Market Sterility Insights** The Sterility segment within the South Korea Compounding Chemotherapy Market plays a crucial role in ensuring the safety and effectiveness of chemotherapy treatments. With an increasing focus on patient safety, sterile compounding methods have gained prominence due to their ability to minimize contamination risks. As South Korea’s healthcare system emphasizes prevention of infections and adherence to stringent regulatory guidelines, the demand for sterile products has significantly risen. Meanwhile, the non-sterile segment also holds importance, catering to specific therapeutic needs and conditions where sterility is less critical. The majority of market growth is propelled by advancements in technology that enhance compounding processes, aligning with the nation’s commitment to improving healthcare outcomes. Furthermore, government initiatives supporting pharmaceuticals and biotechnology sectors directly contribute to the expansion of the overall industry, providing opportunities for innovative compounding solutions. The pharmaceutical legislation in South Korea encourages adherence to good manufacturing practices, which further strengthens the necessity for both sterile and non-sterile products in the compounding chemotherapy domain.Overall, the Sterility segment is instrumental to the efficacy and safety of chemotherapy treatments in South Korea, supporting patient treatment protocols and fostering compliance with industry regulations. **Compounding Chemotherapy Market Technology Insights** The South Korea Compounding Chemotherapy Market is evolving rapidly, particularly focusing on Technology, which plays a crucial role in enhancing treatment efficacy and safety. Within this segment, the presence of robotic arms has gained significant attention, as these systems offer precision and consistency in chemotherapy preparation, reducing variability and potential human error. This technological advancement is creating a more controlled compounding environment, which is essential for oncology treatments.  On the other hand, technologies without robotic arms still hold substantial market relevance, emphasizing manual compounding skills complemented by advanced software systems to ensure accuracy and compliance with safety regulations.The adoption of both methods is driven by the increasing demand for personalized medicine and the growing incidence of cancer, positioning these technologies as vital tools in modern oncology practices. As South Korea focuses on improving cancer care, the evolution of compounding technologies reflects the broader trends in patient-centric care and healthcare efficiency, presenting significant growth opportunities for the industry. The South Korea Compounding Chemotherapy Market segmentation shows a strong inclination towards incorporating innovative therapies that enhance patient outcomes. **South Korea Compounding Chemotherapy Market Key Players and Competitive Insights** The South Korea Compounding Chemotherapy Market is experiencing a significant shift, shaped by the combined forces of innovation, regulatory changes, and competitive dynamics among key players. This market is characterized by a growing demand for personalized treatment options due to the increasing prevalence of cancer among the population. Companies within this sector are continuously striving to enhance their product offerings and operational efficiencies while navigating a complex landscape marked by stringent regulations and evolving healthcare needs. The competitive landscape is characterized by the presence of both established pharmaceutical giants and emerging players, each vying to capture market share through strategic collaborations, product development, and targeted marketing efforts. Bristol-Myers Squibb has established a notable presence in the South Korea Compounding Chemotherapy Market, leveraging its robust portfolio of oncology medications and therapies. The company's strengths lie in its innovative research and development capabilities, which drive the creation of cutting-edge treatments tailored for various cancer types.  Bristol-Myers Squibb consistently invests in local clinical trials and collaborations with medical institutions to strengthen its market foothold and ensure that its therapies not only meet but exceed the regulatory demands of the South Korean market. The firm’s commitment to addressing unmet medical needs through effective treatments fosters loyalty among healthcare professionals and patients alike, enhancing its competitive position in this dynamic sector.Amgen, on the other hand, has made significant strides within the South Korea Compounding Chemotherapy Market with a particular focus on biologics and advanced therapies.  The company's presence is marked by the introduction of key products that have revolutionized treatment paradigms for cancer patients in the region. Amgen's strengths include its expertise in biotechnology and its expansive research initiatives, which contribute to the continuous development of innovative therapies. The company has also engaged in strategic partnerships and mergers to enhance its capabilities and market reach, while also investing in local manufacturing to optimize supply chain efficiency. Amgen's commitment to improving patient outcomes and its emphasis on localized treatment solutions have solidified its standing as a competitive entity within the South Korean oncology landscape. **Key Companies in the South Korea Compounding Chemotherapy Market Include:** **South Korea Compounding Chemotherapy Market Industry Developments** The South Korea Compounding Chemotherapy Market has seen significant developments recently, particularly in the areas of new drug approvals and technological advancements. Major pharmaceutical companies like Bristol-Myers Squibb and Roche Korea are actively engaged in enhancing their product portfolios, focusing on innovative therapies to meet growing demand. In July 2023, Amgen announced the launch of a new biologic therapy aimed at optimizing treatment protocols in oncology.  Additionally, in September 2023, SK Biopharmaceuticals reported an increase in market valuation due to the successful research and development of a groundbreaking chemotherapy drug. In terms of mergers and acquisitions, Hanmi Pharm and Pfizer Korea have been in talks regarding strategic collaborations to bolster their competitive edge, with further details expected to surface in the coming months.  The South Korean government continues to support the biopharmaceutical sector through favorable regulations and funding, reflecting a commitment to advancing healthcare solutions tailored for cancer treatment. This environment fosters not only partnership opportunities but also competition among established players such as Sanofi and Merck, driving market dynamics forward. **South Korea Compounding Chemotherapy Market Segmentation Insights** **Compounding Chemotherapy Market Dose Outlook** **Compounding Chemotherapy Market Delivery Method Outlook** **Compounding Chemotherapy Market Sterility Outlook** **Compounding Chemotherapy Market Technology Outlook** - With Robotic Arms ## Market Drivers ### Rising Cancer Incidence The increasing incidence of cancer in South Korea is a primary driver for the compounding chemotherapy market. According to the Korean Central Cancer Registry, cancer cases have been on the rise, with an estimated 250,000 new cases reported annually. This surge necessitates a greater demand for customized chemotherapy solutions, as patients require tailored treatment regimens. The compounding chemotherapy market is thus positioned to meet this growing need, providing specialized formulations that cater to individual patient profiles. As healthcare providers seek to enhance treatment efficacy, the market is likely to expand, driven by the urgent requirement for innovative and personalized therapeutic options. ### Increased Focus on Patient-Centric Care The shift towards patient-centric care in South Korea is driving the compounding chemotherapy market. Healthcare providers are increasingly recognizing the importance of individualized treatment plans that consider the unique needs of each patient. This trend is reflected in the growing demand for compounded medications that can be tailored to specific cancer types and patient responses. The compounding chemotherapy market is adapting to this paradigm by offering customized solutions that enhance treatment outcomes. As patients become more involved in their treatment decisions, the market is likely to see a rise in the adoption of personalized chemotherapy options, further propelling its growth. ### Advancements in Pharmaceutical Compounding Technological advancements in pharmaceutical compounding are significantly influencing the compounding chemotherapy market. Innovations in compounding techniques and equipment have improved the precision and safety of drug formulations. For instance, the adoption of automated compounding systems has enhanced the accuracy of dosages, reducing the risk of human error. This evolution in the compounding chemotherapy market is crucial, as it allows for the creation of complex formulations that are essential for effective cancer treatment. Furthermore, the integration of quality control measures ensures that compounded medications meet stringent safety standards, thereby fostering trust among healthcare providers and patients alike. ### Growing Demand for Home Healthcare Solutions The increasing demand for home healthcare solutions in South Korea is influencing the compounding chemotherapy market. As patients seek more convenient treatment options, compounded medications that can be administered at home are becoming increasingly popular. This trend is particularly relevant for cancer patients who may prefer to receive treatment in a familiar environment. The compounding chemotherapy market is responding to this demand by developing formulations that are suitable for home use, ensuring that patients have access to effective therapies without the need for frequent hospital visits. This shift towards home healthcare is likely to drive market growth, as it aligns with the evolving preferences of patients and their families. ### Regulatory Support for Compounding Practices Regulatory support for compounding practices in South Korea is a significant driver for the compounding chemotherapy market. The government has implemented guidelines that facilitate the safe and effective compounding of medications, ensuring that patients receive high-quality treatments. These regulations not only promote the integrity of compounded drugs but also encourage pharmacies to invest in compounding capabilities. As a result, the compounding chemotherapy market is experiencing growth, as more healthcare facilities are empowered to provide customized chemotherapy solutions. This regulatory environment fosters innovation and enhances the overall quality of care delivered to cancer patients. ## Future Outlook The [Compounding Chemotherapy Market](https://www.marketresearchfuture.com/reports/compounding-chemotherapy-market-10379) in South Korea is projected to grow at a 6.01% CAGR from 2025 to 2035, driven by technological advancements and increasing cancer prevalence. **New opportunities:** - Development of personalized chemotherapy compounding solutions - Expansion of telepharmacy services for remote patient access - Investment in automated compounding technology to enhance efficiency By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Dose: Chemotherapeutic (Largest) vs. Non-Chemotherapeutics (Fastest-Growing) In the South Korea compounding chemotherapy market, the Chemotherapeutic segment holds the largest market share, reflecting its established presence and deep integration into treatment protocols. This dominance is underscored by the reliance on traditional cancer therapies and the ongoing advancements in chemotherapeutics, which cater to a variety of cancer types, thus maintaining a steady demand. Conversely, the Non-Chemotherapeutics segment is emerging rapidly, driven by increased awareness of alternative treatments and supportive therapies. This growth is further propelled by advancements in immunotherapies and targeted therapies, which offer innovative options alongside conventional chemotherapeutic treatments. As healthcare providers seek comprehensive treatment plans that address patient needs holistically, the Non-Chemotherapeutics segment continues to gain traction and is forecasted to grow significantly in the coming years. Therapeutics: Chemotherapeutic (Dominant) vs. Non-Chemotherapeutics (Emerging) The Chemotherapeutic segment remains dominant within the South Korea compounding chemotherapy market, characterized by a wide array of products that have historically been the cornerstone of cancer treatment. This segment includes various chemotherapeutic agents that are crucial in combating numerous cancer types and are well-integrated into clinical practices. Its strength lies in extensive research backing and a solid regulatory framework, instilling confidence among healthcare providers. On the other hand, the Non-Chemotherapeutics segment is gaining momentum, categorized by novel therapies aimed at enhancing patient quality of life and supporting standard cancer treatments. This emerging segment encompasses immunotherapies and biologics which are becoming increasingly mainstream, driven by an expanding body of clinical evidence and rising patient acceptance. ### By Delivery Method: Gravimetric Automated Compounding Device (Largest) vs. Volumetric Automated Compounding Device (Fastest-Growing) In the South Korea compounding chemotherapy market, the Gravimetric Automated Compounding Device dominates with the largest market share due to its precision and reliability in dosage measurement. This segment appeals to healthcare facilities that prioritize accuracy and compliance with regulatory standards, leading to its widespread adoption across hospitals and clinics that provide chemotherapy services. On the other hand, the Volumetric Automated Compounding Device is gaining traction as the fastest-growing segment. This growth is driven by increasing demand for higher efficiency and reduced compounding time within healthcare settings. As hospitals seek to enhance workflow and minimize human error, volumetric devices are being integrated into more compounding processes, promising to change the landscape of chemotherapy preparation in the coming years. Delivery Method: Gravimetric Automated Compounding Device (Dominant) vs. Volumetric Automated Compounding Device (Emerging) The Gravimetric Automated Compounding Device is characterized by its high accuracy in measuring drug doses, which is crucial in chemotherapy preparations. This segment has established itself as a trusted choice, especially in large hospitals where precise drug formulation is non-negotiable. In contrast, the Volumetric Automated Compounding Device is emerging rapidly due to its ability to streamline processes and enhance compounding speeds. It offers flexibility and ease of use, catering to the growing needs of smaller healthcare facilities. As regulations evolve and the focus on efficiency intensifies, both devices are expected to coexist, each serving a vital role in the future of chemotherapy compounding. ### By Sterility: Sterile (Largest) vs. Non-Sterile (Fastest-Growing) In the South Korea compounding chemotherapy market, the sterile segment holds a significant portion of the overall market share, reflecting its established role in ensuring patient safety and efficacy in cancer treatments. This dominance is attributable to the heightened regulatory standards and the increasing preference for sterile products among healthcare providers. On the other hand, the non-sterile segment is emerging rapidly, capturing interest due to its cost-effectiveness and adaptability in various therapeutic applications. Growing demand for personalized medicine and less stringent manufacturing processes are driving this trend, making non-sterile compounding an attractive option for many providers looking to optimize treatment plans while managing costs. Sterile (Dominant) vs. Non-Sterile (Emerging) The sterile category represents a cornerstone of the South Korea compounding chemotherapy market, known for its rigorous quality control and compliance with stringent health regulations. Hospitals and clinics favor sterile preparations for their critical role in minimizing infection risks during chemotherapy administration. Conversely, the non-sterile segment, while not as established, is gaining traction among compounding pharmacies for its flexibility in formulation and rapid production capabilities. This segment caters to a growing demand for customized treatment regimens, capitalizing on the trend toward more individualized patient care and accessible alternatives in drug formulation. ### By Technology: With Robotic Arms (Largest) vs. Without Robotic Arms (Fastest-Growing) In the South Korea compounding chemotherapy market, the segment utilizing robotic arms holds the largest share, reflecting an increasing trend toward automation and precision in treatment preparation. The advent of technology in healthcare is reshaping the landscape, with robotic arms being favored for their accuracy and efficiency in compounding chemotherapeutics. Conversely, the category without robotic arms is experiencing the fastest growth, driven by a surge in demand for cost-effective and accessible compounding solutions. Healthcare providers are increasingly leveraging traditional methods, which are often quicker to implement and allow for greater flexibility in smaller settings, thus broadening the market appeal of this segment. Technology: With Robotic Arms (Dominant) vs. Without Robotic Arms (Emerging) The segment with robotic arms is characterized by advanced technology that enhances precision and minimizes the risk of human error, making it a dominant force in the South Korea compounding chemotherapy market. Hospitals and clinics that adopt robotic systems often report improved safety and consistency in drug preparation. In contrast, the segment without robotic arms represents an emerging trend, appealing to facilities seeking cost efficiency and faster deployment. This segment is particularly attractive to smaller practices that prioritize affordability and streamlined operations, facilitating its rapid growth as they strive to balance effectiveness with economic viability. ## Competitive Benchmarking The compounding chemotherapy market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and the growing prevalence of cancer. Key players such as Fresenius Kabi (DE), Baxter International (US), and Civica Rx (US) are strategically positioned to leverage their extensive experience in pharmaceutical compounding. Fresenius Kabi (DE) focuses on innovation in drug delivery systems, while Baxter International (US) emphasizes partnerships with healthcare providers to enhance service delivery. Civica Rx (US) aims to address drug shortages through its non-profit model, which collectively shapes a competitive environment that prioritizes patient-centric solutions and operational efficiency.The market structure appears moderately fragmented, with several players competing for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce lead times and enhance responsiveness to market demands. This strategy not only improves supply chain reliability but also allows for better compliance with local regulations, thereby strengthening their competitive positions. In October Fresenius Kabi (DE) announced the launch of a new line of compounded chemotherapy drugs specifically tailored for pediatric patients. This strategic move is significant as it addresses a critical gap in the market, catering to a vulnerable patient demographic that often faces unique treatment challenges. By focusing on this niche, Fresenius Kabi (DE) not only enhances its product portfolio but also reinforces its commitment to patient safety and efficacy in treatment. In September Baxter International (US) expanded its partnership with a leading South Korean hospital network to streamline the delivery of compounded chemotherapy solutions. This collaboration is pivotal as it allows Baxter to integrate its services more deeply into the healthcare ecosystem, ensuring that patients receive timely and effective treatments. Such strategic alliances are likely to enhance Baxter's market presence and operational capabilities in the region. In August Civica Rx (US) secured a significant funding round aimed at expanding its production capabilities for compounded medications. This investment is crucial as it positions Civica Rx (US) to scale its operations and meet the increasing demand for compounded chemotherapy drugs. The funding will likely facilitate advancements in technology and production processes, further solidifying Civica's role in mitigating drug shortages and enhancing access to essential therapies. As of November the competitive trends in the compounding chemotherapy market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in operations. Companies are forming strategic alliances to enhance their technological capabilities and improve patient outcomes. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver high-quality, personalized treatment solutions efficiently. ## Recent News & Developments The South Korea Compounding Chemotherapy Market has seen significant developments recently, particularly in the areas of new drug approvals and technological advancements. Major pharmaceutical companies like Bristol-Myers Squibb and Roche Korea are actively engaged in enhancing their product portfolios, focusing on innovative therapies to meet growing demand. In July 2023, Amgen announced the launch of a new biologic therapy aimed at optimizing treatment protocols in oncology.  Additionally, in September 2023, SK Biopharmaceuticals reported an increase in market valuation due to the successful research and development of a groundbreaking chemotherapy drug. In terms of mergers and acquisitions, Hanmi Pharm and Pfizer Korea have been in talks regarding strategic collaborations to bolster their competitive edge, with further details expected to surface in the coming months.  The South Korean government continues to support the biopharmaceutical sector through favorable regulations and funding, reflecting a commitment to advancing healthcare solutions tailored for cancer treatment. This environment fosters not only partnership opportunities but also competition among established players such as Sanofi and Merck, driving market dynamics forward. ## Report Scope | MARKET SIZE 2024 | 10.6(USD Million) | | --- | --- | | MARKET SIZE 2025 | 11.24(USD Million) | | MARKET SIZE 2035 | 20.15(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.01% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Fresenius Kabi (DE), Baxter International (US), Civica Rx (US), PharMEDium Services (US), Compounding Pharmacy of America (US), Avella Specialty Pharmacy (US), PillPack (US), Onco360 (US) | | Segments Covered | Dose, Delivery Method, Sterility, Technology | | Key Market Opportunities | Emerging personalized therapies and regulatory support enhance growth potential in the compounding chemotherapy market. | | Key Market Dynamics | Regulatory changes and technological advancements drive growth in the compounding chemotherapy market in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the overall market valuation for the compounding chemotherapy market in 2024?** A: The overall market valuation was $10.6 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The projected market valuation for 2035 is $20.15 Million. **Q: What is the expected CAGR for the compounding chemotherapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 6.01%. **Q: Which companies are considered key players in the compounding chemotherapy market?** A: Key players include Fresenius Kabi, Baxter International, Civica Rx, and others. **Q: What were the segment valuations for chemotherapeutic and non-chemotherapeutic doses in 2024?** A: In 2024, chemotherapeutic doses were valued at $6.36 Million, while non-chemotherapeutic doses were valued at $4.24 Million. **Q: How do the valuations for gravimetric and volumetric automated compounding devices compare?** A: Gravimetric automated compounding devices were valued at $4.24 Million, whereas volumetric devices were valued at $6.36 Million in 2024. **Q: What is the market valuation for sterile versus non-sterile compounding in 2024?** A: In 2024, sterile compounding was valued at $6.36 Million, while non-sterile compounding was valued at $4.24 Million. **Q: What are the projected valuations for compounding technology with and without robotic arms?** A: Compounding technology with robotic arms was valued at $3.18 Million, while without robotic arms, it was valued at $7.42 Million in 2024. **Q: What does the growth trend indicate for the compounding chemotherapy market in South Korea?** A: The growth trend suggests a robust increase, with the market expected to reach $20.15 Million by 2035. **Q: How does the market's performance in 2024 set the stage for future growth?** A: The performance in 2024, with a valuation of $10.6 Million, indicates a solid foundation for future growth through 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-compounding-chemotherapy-market-53234*